Latest news with #Qiagen
Yahoo
3 days ago
- Business
- Yahoo
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Qiagen (QGEN). Shares have added about 8.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 6.92% due to these changes. Currently, Qiagen has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Qiagen has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Qiagen belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), has gained 12.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Incyte reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +19.5%. EPS of $1.16 for the same period compares with $0.64 a year ago. For the current quarter, Incyte is expected to post earnings of $1.38 per share, indicating a change of +175.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Incyte. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
4 days ago
- Business
- Business Insider
Qiagen, Tracer Biotechnologies announce strategic partnership
Tracer Biotechnologies is pleased to announce a strategic partnership with Qiagen (QGEN) to co-develop and commercialize minimal residual disease assays for solid tumors on Qiagen's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples. Confident Investing Starts Here:
Yahoo
5 days ago
- Business
- Yahoo
Affordable Sequencing Instruments Expand Market Access for Smaller Labs
Advances in NGS, affordable instruments like Illumina MiSeq, AI-driven bioinformatics, and strategic partnerships drive growth in the microbiome sequencing market. The report details market trends, factors, regional insights, and profiles of major players including Illumina, Qiagen, and Thermo Fisher. Microbiome Sequencing Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Sequencing Market" report has been added to global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029. Next-generation sequencing (NGS) technologies have transformed the discipline by providing high-throughput, affordable analysis of microbial communities with the ability to sequence millions of DNA fragments at once. By combining microbiome data with genomics, proteomics and metabolomics, researchers have gained a full understanding of microbial functions in health and disease. In addition, the creation of smaller, less expensive sequencing instruments, such as Illumina's MiSeq i100 line, has placed sequencing technologies within reach of smaller research and clinical labs. Organizations are making significant investments in R&D to create affordable sequencing platforms, bioinformatics software and data analysis solutions enabled by AI to enhance precision and efficiency. Strategic partnerships and grants also enhance research in microbiomes, leading to the development of new applications in precision medicine and microbiome ScopeThe report analyzes the microbiome sequencing market by component, sequencing technology, laboratory type, application and end user, offering insights into key trends and growth drivers. The study concludes with an analysis of leading companies and their report analyzes the macroeconomic factors affecting the market. Market drivers, restraints and opportunities are identified. The report covers the regulatory landscape, recent technologies and patents in the market, as well as innovations in products and performance. The report also covers the competitive landscape, ESG factors and profiles of leading report includes: 50 data tables and 51 additional tables Analyses of the global market trends for microbiome sequencing technologies, with revenue data from 2021-2024, and projected CAGRs through 2029 Estimates of the size and revenue prospects for the global market, along with a market share analysis by sequencing technology, component, laboratory type, application, end user and region Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses A look at the emerging trends and opportunities in microbiome-based therapeutics, clinical trials Evaluation of recent patent activity and key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of leading companies including Illumina, Qiagen, Thermo Fisher Scientific, Oxford Nanopore Technologies and PacBio. Key Attributes: Report Attribute Details No. of Pages 124 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $1.5 Billion Forecasted Market Value (USD) by 2029 $3.7 Billion Compound Annual Growth Rate 19.3% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Outlook Macroeconomic Analysis Impact of U.S.-China Trade War Chapter 3 Market Dynamics Market Drivers Decreasing Cost per Genome Government Initiatives and Funding Advances in Sequencing Technology Market Restraints Data Complexity and Bioinformatics Challenges Lack of Standardized Protocols and Reference Databases Lack of Grant Funding Market Opportunities Personalized Medicine and Diagnostics Drug Discovery and Development Agriculture and the Food Industry Chapter 4 Regulatory Landscape Chapter 5 Emerging Technologies and Patent Analysis Emerging Technologies Nanopore Sequencing SMRT Sequencing FACS with Microfluidics Metatranscriptome Sequencing Patent Analysis Regional Patterns Chapter 6 Market Segment Analysis Market Trends Segmentation Breakdown Microbiome Sequencing: Global Markets Market Analysis by Sequencing Technology High-throughput Sequencing Sanger Sequencing Third-Generation Sequencing Market Analysis by Component Reagents and Kits Instruments Market Analysis by Laboratory Type Wet Labs Dry Labs Market Analysis by Application Disease Diagnosis Research Personalized Medicine Drug Discovery Genetic Screening Other Applications Market Analysis by End User Pharmaceutical and Biotechnology Academic Centers and Research Institutes Other End Users Market Breakdown by Region North America Europe Asia-Pacific MEA South America Chapter 7 Competitive Landscape Key Suppliers and Manufacturers Ranking of Companies in the Microbiome Sequencing Industry Strategic Analysis Chapter 8 Environmental, Social, and Governance (ESG) Perspective Sustainability in the Microbiome Sequencing Market ESG Risks and Ratings: Understanding the Data Analyst's Viewpoint Company Profiles BaseClear CD Genomics Charles River Laboratories CosmosID Crown Bioscience Danaher Corp. Eurofins Scientific Illumina Inc. Merieux NutriSciences Microbiome Insights Novogene Co. Ltd. Oxford Nanopore Technologies plc PacBio QIAGEN Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Microbiome Sequencing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Affordable Sequencing Instruments Expand Market Access for Smaller Labs
Advances in NGS, affordable instruments like Illumina MiSeq, AI-driven bioinformatics, and strategic partnerships drive growth in the microbiome sequencing market. The report details market trends, factors, regional insights, and profiles of major players including Illumina, Qiagen, and Thermo Fisher. Microbiome Sequencing Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Sequencing Market" report has been added to global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029. Next-generation sequencing (NGS) technologies have transformed the discipline by providing high-throughput, affordable analysis of microbial communities with the ability to sequence millions of DNA fragments at once. By combining microbiome data with genomics, proteomics and metabolomics, researchers have gained a full understanding of microbial functions in health and disease. In addition, the creation of smaller, less expensive sequencing instruments, such as Illumina's MiSeq i100 line, has placed sequencing technologies within reach of smaller research and clinical labs. Organizations are making significant investments in R&D to create affordable sequencing platforms, bioinformatics software and data analysis solutions enabled by AI to enhance precision and efficiency. Strategic partnerships and grants also enhance research in microbiomes, leading to the development of new applications in precision medicine and microbiome ScopeThe report analyzes the microbiome sequencing market by component, sequencing technology, laboratory type, application and end user, offering insights into key trends and growth drivers. The study concludes with an analysis of leading companies and their report analyzes the macroeconomic factors affecting the market. Market drivers, restraints and opportunities are identified. The report covers the regulatory landscape, recent technologies and patents in the market, as well as innovations in products and performance. The report also covers the competitive landscape, ESG factors and profiles of leading report includes: 50 data tables and 51 additional tables Analyses of the global market trends for microbiome sequencing technologies, with revenue data from 2021-2024, and projected CAGRs through 2029 Estimates of the size and revenue prospects for the global market, along with a market share analysis by sequencing technology, component, laboratory type, application, end user and region Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses A look at the emerging trends and opportunities in microbiome-based therapeutics, clinical trials Evaluation of recent patent activity and key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of leading companies including Illumina, Qiagen, Thermo Fisher Scientific, Oxford Nanopore Technologies and PacBio. Key Attributes: Report Attribute Details No. of Pages 124 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $1.5 Billion Forecasted Market Value (USD) by 2029 $3.7 Billion Compound Annual Growth Rate 19.3% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Outlook Macroeconomic Analysis Impact of U.S.-China Trade War Chapter 3 Market Dynamics Market Drivers Decreasing Cost per Genome Government Initiatives and Funding Advances in Sequencing Technology Market Restraints Data Complexity and Bioinformatics Challenges Lack of Standardized Protocols and Reference Databases Lack of Grant Funding Market Opportunities Personalized Medicine and Diagnostics Drug Discovery and Development Agriculture and the Food Industry Chapter 4 Regulatory Landscape Chapter 5 Emerging Technologies and Patent Analysis Emerging Technologies Nanopore Sequencing SMRT Sequencing FACS with Microfluidics Metatranscriptome Sequencing Patent Analysis Regional Patterns Chapter 6 Market Segment Analysis Market Trends Segmentation Breakdown Microbiome Sequencing: Global Markets Market Analysis by Sequencing Technology High-throughput Sequencing Sanger Sequencing Third-Generation Sequencing Market Analysis by Component Reagents and Kits Instruments Market Analysis by Laboratory Type Wet Labs Dry Labs Market Analysis by Application Disease Diagnosis Research Personalized Medicine Drug Discovery Genetic Screening Other Applications Market Analysis by End User Pharmaceutical and Biotechnology Academic Centers and Research Institutes Other End Users Market Breakdown by Region North America Europe Asia-Pacific MEA South America Chapter 7 Competitive Landscape Key Suppliers and Manufacturers Ranking of Companies in the Microbiome Sequencing Industry Strategic Analysis Chapter 8 Environmental, Social, and Governance (ESG) Perspective Sustainability in the Microbiome Sequencing Market ESG Risks and Ratings: Understanding the Data Analyst's Viewpoint Company Profiles BaseClear CD Genomics Charles River Laboratories CosmosID Crown Bioscience Danaher Corp. Eurofins Scientific Illumina Inc. Merieux NutriSciences Microbiome Insights Novogene Co. Ltd. Oxford Nanopore Technologies plc PacBio QIAGEN Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Microbiome Sequencing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research
On Friday, Qiagen (NYSE:QGEN) announced a new commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for oncology research applications. The partnership aims to use Qiagen's global reach and automation expertise with ID Solutions' assay development and manufacturing capabilities to strengthen Qiagen's position in oncology research. A scientist in a lab coat using the latest medical equipment for nucleic acid purification. Under the terms of the agreement, ID Solutions will produce and supply dPCR assays specifically for non-clinical research use on Qiagen's QIAcuity platforms. These assays are designed to identify multiple mutations simultaneously in cell-free DNA extracted from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue samples. Qiagen will initially market these kits in Europe, with plans for future expansion into other regions. The newly added assays will complement Qiagen's current PanCancer Kits for detecting various hallmark mutations in DNA from diverse sample types, as well as over 200 locked nucleic acid (LNA) mutation assays. For customers, this collaboration translates into streamlined access to ready-to-use assays optimized for QIAcuity in non-clinical oncology research, which promise results in less than a day. Qiagen (NYSE:QGEN) provides sample-to-insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. While we acknowledge the potential of QGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QGEN and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
